EQUITY RESEARCH - RESULTS FLASH



THAILAND / HEALTH CARE SERVICES

CHG TB



THB3.90

THB2.84

+37.3%

+15.0%

1Q24 results at first glance

CHG – 1Q24 core profit grew by 10% y-y to THB264m, in line with our estimate

Highlights

- CHG reported a core profit of THB264m in 1Q24 (+10% y-y, -4% qq), in line with our estimate.
- Revenue grew 18% y-y. Cash patient revenue grew by 19% y-y. SSO revenue grew by 11% y-y.
- COGS grew by 17% y-y, while SG&A jumped by 29% y-y due to an unrealized FX loss of THB21m. As a result, the EBITDA margin declined to 23% in 1Q24 (vs 24% in 1Q23), pressured by a loss from CHG Mae Sot and an FX loss. Excluding the FX loss, core profit would be cTHB280m (+17% y-y).
- 1Q24 core profit accounted for 20% of our full-year forecast of THB1.3b.

Outlook

We expect the y-y core profit growth momentum to continue into 2Q24 with the low base from last year. In addition, we expect the loss from CHG Mae Sot to narrow, especially in 2H24, leading to strong growth in 2H24.

KEY STOCK DATA

2023	2024E	2025E	2026E
7,730	8,560	9,136	9,749
1,046	1,300	1,488	1,632
0.10	0.12	0.14	0.15
-	10.1	13.8	19.0
1,822	2,189	2,438	2,649
1,046	1,300	1,488	1,632
0.10	0.12	0.14	0.15
(62.4)	24.3	14.5	9.7
29.9	24.0	21.0	19.1
2.5	2.5	2.9	3.1
17.0	14.0	12.3	11.1
4.2	3.9	3.6	3.3
(8.2)	(12.1)	(18.3)	(23.8)
13.9	16.7	17.7	17.9
	7,730 1,046 0.10 - 1,822 1,046 0.10 (62.4) 29.9 2.5 17.0 4.2 (8.2)	7,730 8,560 1,046 1,300 0.10 0.12 - 10.1 1,822 2,189 1,046 1,300 0.10 0.12 (62.4) 24.3 29.9 24.0 2.5 2.5 17.0 14.0 4.2 3.9 (8.2) (12.1)	7,730 8,560 9,136 1,046 1,300 1,488 0.10 0.12 0.14 - 10.1 13.8 1,822 2,189 2,438 1,046 1,300 1,488 0.10 0.12 0.14 (62.4) 24.3 14.5 29.9 24.0 21.0 2.5 2.5 2.9 17.0 14.0 12.3 4.2 3.9 3.6 (8.2) (12.1) (18.3)

TARGET PRICE

UP/DOWNSIDE

TP vs CONSENSUS

CLOSE



Share price performance	1 Month	3 Month	12 Month		
Absolute (%)	(1.4)	(4.7)	(15.0)		
Relative to country (%)	0.3	(3.4)	(3.3)		
Mkt cap (USD m)			849		
3m avg. daily turnover (USD m)			1.9		
Free float (%)			43		
Major shareholder	Kannikar Plussind (18%)				
12m high/low (THB)			3.40/2.60		
Issued shares (m)			11,000.00		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: CHG – 1Q24 results summary

	1Q23	2Q23	3Q23	4Q23	1Q24	Cha	nge	2023	2024E
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)				
Revenue	1,716	1,799	2,093	2,123	2,021	(5)	18	7,730	8,560
Cost of sales (Incl. depreciation)	(1,276)	(1,380)	(1,486)	(1,580)	(1,498)	(5)	17	(5,723)	(6,212)
Gross profit	440	418	607	543	523	(4)	19	2,008	2,347
SG&A	(200)	(222)	(246)	(243)	(259)	7	29	(911)	(957)
Operating profit	240	196	361	300	264	(12)	10	1,097	1,390
Other operating income	73	70	77	65	85	31	18	284	295
Interest income	1	3	1	4	1			9	6
Equity income	(3)	(2)	(5)	(9)	(9)	(1)	153	(19)	(10)
EBIT	309	267	434	361	342	(5)	10	1,370	1,682
Interest expense	(4)	(5)	(7)	(9)	(5)	(41)	25	(24)	(18)
EBT	305	262	427	352	337	(4)	10	1,346	1,664
Income tax	(60)	(56)	(90)	(73)	(76)	3	26	(279)	(342)
Minority interests	(5)	(0)	(11)	(5)	3	(152)	(154)	(21)	(22)
Core profit	240	206	326	274	264	(4)	10	1,046	1,300
Extraordinaries									
Net income	240	206	326	274	264	(4)	10	1,046	1,300
Core EPS (THB)	0.02	0.02	0.03	0.02	0.02	(4)	10	0.10	0.12
No of share (m)	11,000	11,000	11,000	11,000	11,000	0	0	11,000	11,000
Cost (Excl. depreciation)	(1,177)	(1,276)	(1,370)	(1,459)	(1,377)	(6)	17	(5,282)	(5,709)
Depreciation & amortization	(99)	(104)	(117)	(121)	(121)	0	22	(441)	(503)
EBITDA	411	370	554	486	470	(3)	14	1,822	2,189
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)
Gross margin	26	23	29	26	26	0	0	26	27
SG&A/Revenue	12	12	12	11	13	1	1	12	11
EBITDA margin	24	21	26	23	23	0	(1)	24	26
Net profit margin	14	11	16	13	13	0	(1)	14	15
Operating stats	(y-y %)	(y-y %)	(y-y %)	(y-y %)					
SSO revenue	19	23	8	11					
SSO registered members ('000)	525	528	529	530					
SSO revenue per head	10	17	5	8					
Cash-OPD revenue	(41)	(20)	(6)	24					
Cash-OPD visit number	(19)	(7)	2	11					
Cash-OPD revenue per head	(26)	(13)	(8)	12					
Cash-IPD revenue	(5)	5	24	22					
Cash-IPD admission number	9	30	29	29					
Cash-IPD revenue per head	(13)	(19)	(4)	(6)					

Sources: CHG; FSSIA estimates

Financial Statements

Chularat Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	10,103	7,730	8,560	9,136	9,749
Cost of goods sold	(5,908)	(5,723)	(6,212)	(6,544)	(6,933)
Gross profit	4,195	2,008	2,347	2,592	2,815
Other operating income	305	284	295	304	313
Operating costs	(935)	(911)	(957)	(994)	(1,051)
Operating EBITDA	3,947	1,822	2,189	2,438	2,649
Depreciation	(382)	(441)	(503)	(536)	(572)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	3,565	1,381	1,686	1,902	2,078
Net financing costs	(10)	(15)	(12)	3	5
Associates	(1)	(19)	(10)	(4)	1
Recurring non-operating income	(1)	(19)	(10)	(4)	1
Non-recurring items	0	0	0	0	0
Profit before tax	3,554	1,346	1,664	1,901	2,084
Tax	(703)	(279)	(342)	(389)	(426)
Profit after tax	2,850	1,067	1,322	1,512	1,658
Minority interests	(72)	(21)	(22)	(24)	(26)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	2,778	1,046	1,300	1,488	1,632
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	2,778	1,046	1,300	1,488	1,632
Per share (THB)					
Recurring EPS *	0.25	0.10	0.12	0.14	0.15
Reported EPS	0.25	0.10	0.12	0.14	0.15
DPS	0.16	0.07	0.07	0.08	0.09
Diluted shares (used to calculate per share data)	11,000	11,000	11,000	11,000	11,000
Growth					
Revenue (%)	(14.0)	(23.5)	10.7	6.7	6.7
Operating EBITDA (%)	(30.1)	(53.8)	20.2	11.4	8.6
Operating EBIT (%)	(32.7)	(61.3)	22.1	12.8	9.2
Recurring EPS (%)	(33.9)	(62.4)	24.3	14.5	9.7
Reported EPS (%)	(33.9)	(62.4)	24.3	14.5	9.7
Operating performance					
Gross margin inc. depreciation (%)	41.5	26.0	27.4	28.4	28.9
Gross margin exc. depreciation (%)	45.3	31.7	33.3	34.2	34.7
Operating EBITDA margin (%)	39.1	23.6	25.6	26.7	27.2
Operating EBIT margin (%)	35.3	17.9	19.7	20.8	21.3
Net margin (%)	27.5	13.5	15.2	16.3	16.7
Effective tax rate (%)	19.8	20.4	20.4	20.4	20.4
Dividend payout on recurring profit (%)	63.3	73.6	60.0	60.0	60.0
Interest cover (X)	349.5	88.7	143.2	(729.4)	(382.9)
Inventory days	18.5	20.8	22.4	22.7	22.6
Debtor days	24.8	38.5	39.1	38.3	35.9
Creditor days	55.9	60.3	59.5	60.2	60.0
Operating ROIC (%)	47.1	15.9	18.4	20.5	22.2
ROIC (%)	45.1	14.9	17.5	19.6	21.3
ROE (%)	36.8	13.9	16.7	17.7	17.9
ROA (%)	27.4	10.5	13.0	14.2	14.5
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	5,160	5,025	5,541	5,993	6,482
SSO patient revenue	2,149	2,461	2,763	2,875	2,990
NHSO patient revenue	2,794	244	256	269	277

Sources: Chularat Hospital; FSSIA estimates

Financial Statements

Chularat Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
Recurring net profit	2,778	1,046	1,300	1,488	1,63
Depreciation	382	441	503	536	57
Associates & minorities	-	-	-	-	
Other non-cash items	117	30	22	24	2
Change in working capital	(696)	435	(147)	(43)	(41
Cash flow from operations	2,582	1,951	1,678	2,006	2,18
Capex - maintenance Capex - new investment	(777)	(1,451)	(514)	(548)	(585
Net acquisitions & disposals	(142)	19	0	0	
Other investments (net)	-	-	-	-	
Cash flow from investing	(919)	(1,432)	(514)	(548)	(585
Dividends paid	(2,805)	(1,045)	(770)	(780)	(893
Equity finance	0	0	0	0	,
Debt finance	356	(120)	(705)	0	
Other financing cash flows	(3)	44	(22)	(24)	(26
Cash flow from financing	(2,452)	(1,121)	(1,497)	(804)	(919
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	
Net other adjustments	0	0	0	0	
Movement in cash	(789)	(601)	(333)	653	68
Free cash flow to firm (FCFF)	1,679.02	543.33	1,181.99	1,459.48	1,605.5
Free cash flow to equity (FCFE)	2,016.07	443.25	436.94	1,432.98	1,577.1
Per share (THB)					
FCFF per share	0.15	0.05	0.11	0.13	0.1
FCFE per share	0.18	0.04	0.04	0.13	0.1
Recurring cash flow per share	0.30	0.14	0.17	0.19	0.2
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
Tangible fixed assets (gross)	7,867	9,318	9,831	10,379	10,96
Less: Accumulated depreciation	(2,987)	(3,414)	(3,917)	(4,453)	(5,025
Tangible fixed assets (net)	4,880	5,903	5,914	5,926	5,93
ntangible fixed assets (net)	47	104	104	104	10
Long-term financial assets	-	-	-	-	-
nvest. in associates & subsidiaries	142	122	122	122	12
Cash & equivalents	2,001	1,399	1,066	1,719	2,40
A/C receivable	757	874	960	960	96
nventories	265	336	364	383	40
Other current assets	2,036	1,436	1,590	1,697	1,81
Current assets	5,058	4,046	3,980	4,759	5,58
Other assets	152	88	88	88	8
Total assets	10,280	10,264	10,209	11,000	11,83
Common equity	7,523	7,525	8,054	8,762	9,50
Minorities etc.	341	406	406	406	40
Total shareholders' equity	7,864	7,931	8,461	9,168	9,90
Long term debt	470	705	0	0	0.4
Other long-term liabilities	233	247	247	247	24
Long-term liabilities	704	953	247	247	1.07
A/C payable Short term debt	851 400	894 45	966 45	1,017 45	1,07 4
Other current liabilities	462	442	490	522	55
Current liabilities	1,712	1,381	1,501	1,584	1,67
Total liabilities and shareholders' equity	10,280	10,264	10,209	11,000	11,83
Net working capital	1,745	1,311	1,458	1,500	1,54
nvested capital	6,967	7,529	7,687	7,741	7,79
Includes convertibles and preferred stock which is be	ing treated as debt				
Per share (THB)					
Book value per share	0.68	0.68	0.73	0.80	8.0
Fangible book value per share	0.68	0.67	0.73	0.79	0.6
Financial strength	0.00	0.01	0.12	0.10	0.0
Net debt/equity (%)	(14.4)	(8.2)	(12.1)	(18.3)	(23.
Net debt/total assets (%)	(11.0)	(6.3)	(10.0)	(15.2)	(19.
Current ratio (x)	3.0	2.9	2.7	3.0	3
CF interest cover (x)	198.7	29.9	38.3	(549.5)	(289.
/aluation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	11.2	29.9	24.0	21.0	19
Recurring P/E @ target price (x) *	15.4	41.0	33.0	28.8	26
Reported P/E (x)	11.2	29.9	24.0	21.0	19
Dividend yield (%)	5.6	2.5	2.5	2.9	3
Price/book (x)	4.2	4.2	3.9 3.0	3.6	3
Price/tangible book (x) EV/EBITDA (x) **	4.2 7.7	4.2 17.0	3.9 14.0	3.6 12.3	3 11
=V/EBITDA (x) *** EV/EBITDA @ target price (x) **	7.7 10.7	17.0 23.4	14.0 19.3	12.3 17.1	11 15
_ v/にいけいれ (w target price (x)	10.7	23.4	18.3	17.1	15
EV/invested capital (x)	4.4	4.1	4.0	3.9	3

Sources: Chularat Hospital; FSSIA estimates

Chularat Hospital PCL (CHG TB)



Exhibit 2: FSSIA ESG score implication

38.25 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA			Domes	stic ratings	;		Global ratings					Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	_	2.21	2.34
BESG environmental pillar score	_	_	4.04	4.18
BESG social pillar score	_	_	0.74	0.79
BESG governance pillar score	_	_	4.19	4.49
ESG disclosure score	36.82	36.82	41.54	50.24
Environmental disclosure score	16.49	16.49	17.67	32.92
Social disclosure score	12.70	12.70	19.41	30.29
Governance disclosure score	81.10	81.10	87.36	87.36
Environmental				
Emissions reduction initiatives	Yes	Yes	Yes	Yes
Climate change policy	No	No	Yes	Yes
Climate change opportunities discussed	No	No	No	No
Risks of climate change discussed	No	No	No	No
GHG scope 1	0	0	0	0
GHG scope 2 location-based	4	4	4	4
GHG Scope 3	1	1	1	1
Carbon per unit of production	_	_	_	_
Biodiversity policy	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes
Total energy consumption	_	_	_	_
Renewable energy use	_	_	_	_
Electricity used	4	4	4	7
Fuel used - natural gas	_	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$

Exhibit 5: ESG score by Bloomberg (cont.)

FY 2020	FY 2021	FY 202
No	No	١
Yes	Yes	Ye
0	0	
1	1	
0	0	
_	_	
No	No	1
No	Yes	Ye
73	80	-
Yes	Yes	Y
Yes	Yes	Y
No	No	1
Yes	Yes	Y
Yes	Yes	Y
No	No	1
_	84	
_	_	
Yes	Yes	Υ
Yes	Yes	Υ
Yes	Yes	Υ
_	_	
_	_	
Yes	Yes	Y
No	No	
3,616	3,871	4,5
	20	.,0
_	32,904	85,8
No	No	1
12	12	
4	4	
2	2	
11	11	
Yes	Yes	Y
7	7	·
100	95	1
3	3	
No	No	ı
62	63	'
78	79	
6	6	
2	2	
No 3	No 3	l
3	3	
5	5	4
100	100	1
5	5	
4	4	
2	2	
100	83	1
5	5	
2	2	
100	83	1
	No	

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating				
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process bas from the ann	ed on the comp nual S&P Globa	ransparent, rules-based panies' Total Sustainabili al Corporate Sustainabilit anies within each industry	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I	Assessment (C ess than 45% ny are disqual	he annual S&P (SA) for DJSI. Co of the S&P Glob ified. The constit iverse.	mpanies with al ESG Score	an S&P Globa of the highest
Sustainability nvestment List (THSI) by The Stock Exchange of Thailand (SET)	managing b Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tra must pass the ar trading of the shareholders, some key disque ependent direct related to CG,	ity in Environmental and ansparency in Governand preemptive criteria, with e board members and en and combined holding nalifying criteria include: 1 tors and free float violatic social & environmental in annings in red for > 3 year	ce, updated annually. two crucial conditions: kecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against th nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.				
CG Score by Thai nstitute of Directors Association Thai IOD)	annually by Thailand (SI	the Thai IOD, v	n in sustainable developn with support from the Sto s are from the perspectiv s.	ck Exchange of	Good (80-89), and not rated f equitable treate	3 for Good (70 or scores belo ment of sharel 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 ssure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), le rights; 2) an); 3) the role o
AGM level By Thai nvestors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	re incorporated and sufficiently and sufficiently are CG component AGM proceduland after the most after information assesses by; and 3) opennesses.	thich shareholders' rights into business operations of disclosed. All form impoents to be evaluated annuares before the meeting (10%). (The first as ion for voting; and 2) facilitating the ease of attending mess for Q&A. The third involves, resolutions and voting res	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be eetings; 2) transparency s the meeting minutes that	nt 3 n be				
Fhai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key control e Certification is leciding to become intent to kick off a ncluding risk asse	Checklist include corruptions, and the monitoring and so good for three years. The a CAC certified member stain 18-month deadline to subsessment, in place of policy and whistleblowing stakeholders.)	nd developing of art by submitting a mit the CAC Checklist for ad control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.				
Morningstar Sustainalytics	based on ar risk is unma	n assessment o naged. <i>Sources</i>	sk rating provides an ove of how much of a compan to be reviewed include corpo er media, NGO reports/webs	ny's exposure to ESG orate publications and			score is the sum higher ESG risk		ed risk. The
	information, co		r, ESG controversies, issuer t		NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+
ESG Book	positioned to the principle helps explai over-weighti	o outperform ov of financial ma n future risk-ad	ustainable companies the ver the long term. The me ateriality including informa justed performance. Mat th higher materiality and in thy basis.	ethodology considers ation that significantly teriality is applied by	scores using m	ateriality-base	lated as a weight ed weights. The s ndicating better p	core is scaled	
<u>MSCI</u>			neasure a company's ma d laggards according to t						nethodology to
	AAA	8.571-10.000)						
	AA	7.143-8.570	Leader:	leading its industry in m	anaging the most s	ignilicant ESG fi	sks and opportunitie	:5	
	Α	5.714-7.142							
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	al track record of m	anaging the mos	st significant ESG ris	sks and opportu	nities relative to
	ВВ	2.857-4.285		, .					
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	sure and failure t	o manage significar	it ESG risks	
	CCC	0.000-1.428	99****	55 5 ··· ··· ·· · · · · · · · · · · · ·	g., expoc		gg3di		
loody's ESG olutions	believes tha	t a company in	ree to which companies t tegrating ESG factors int r shareholders over the r	to its business model and					
Refinitiv ESG rating	based on pu	ıblicly available	and objectively measure and auditable data. The a publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of t	
S&P Global			e is a relative score mea n the same industry clas				of ESG risks, op	portunities, ar	d impacts
Bloomberg	ESG Score		score is based on Bloom	ating the company's aggr mberg's view of ESG fina the weights are determin	ncial materiality.	The score is	a weighted gener	alized mean (power mean)
							nges from 0 for n		

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION


Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
20-May-2021	BUY	4.00	09-Feb-2023	BUY	4.40	03-Nov-2023	BUY	4.00
05-Aug-2021	BUY	4.70	03-Aug-2023	BUY	3.90	30-Jan-2024	BUY	3.90

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Chularat Hospital	CHG TB	THB 2.84	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 13-May-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.